SGMT•benzinga•
Goldman Sachs Maintains Buy on Sagimet Biosciences, Lowers Price Target to $23
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 16, 2024 by benzinga